CN Patent

CN113121539A — 一种pf06651600的制备方法

Assigned to Jiangsu Ailikang Pharmaceutical Technology Co ltd · Expires 2021-07-16 · 5y expired

What this patent protects

本发明提供了一种PF06651600的制备方法，具体而言，以纯对映异构体（3R，6S）‑1‑苄基‑6‑甲基哌啶‑3‑胺为起始原料，经过与4‑氯吡咯并[2,3‑D]嘧啶反应，氢化脱苄，与丙烯酰氯反应得到目标物PF06651600。本发明以对映异构体为原料，避免了后期昂贵的手性色谱分离，反应条件温和，可控性高，具有良好的工业化应用前景。

USPTO Abstract

本发明提供了一种PF06651600的制备方法，具体而言，以纯对映异构体（3R，6S）‑1‑苄基‑6‑甲基哌啶‑3‑胺为起始原料，经过与4‑氯吡咯并[2,3‑D]嘧啶反应，氢化脱苄，与丙烯酰氯反应得到目标物PF06651600。本发明以对映异构体为原料，避免了后期昂贵的手性色谱分离，反应条件温和，可控性高，具有良好的工业化应用前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN113121539A
Jurisdiction
CN
Classification
—
Expires
2021-07-16
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Ailikang Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.